Publications by authors named "David Oliver Scourfield"
Cancers (Basel)
December 2022
Article Synopsis
- mTORC1 inhibitors are not a complete cure for tuberous sclerosis complex (TSC), indicating the need for alternative therapeutic approaches.
- Research shows that redox factor-1 (Ref-1) is involved in TSC's disease mechanisms, affecting important transcription factors linked to inflammation, tumor growth, and other processes.
- The Ref-1 inhibitor APX3330 shows promise in reducing tumor cell activity and invasion without affecting mTORC1, suggesting that targeting Ref-1 and its pathways could enhance treatment strategies for TSC.
